TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-11-14

AUTHORS

Jamie L. Croucher, Radhika Iyer, Nanxin Li, Valentina Molteni, Jon Loren, W. Perry Gordon, Tove Tuntland, Bo Liu, Garrett M. Brodeur

ABSTRACT

Purpose Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50–60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.Methods We tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino–TMZ).ResultsGNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50 nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p < 0.0001 for mice treated at 40 or 100 mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino–TMZ, p < 0.0071 compared to Irino–TMZ alone).ConclusionsOur data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino–TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity. More... »

PAGES

131-141

References to SciGraph publications

  • 2003-03. Neuroblastoma: biological insights into a clinical enigma in NATURE REVIEWS CANCER
  • 1999-06. Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostate cancer cells in CLINICAL & EXPERIMENTAL METASTASIS
  • 1997-06. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1998-02. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma in NATURE GENETICS
  • 1995-03. A BDNF autocrine loop in adult sensory neurons prevents cell death in NATURE
  • 2003-08-28. Nerve growth factor overexpression and autocrine loop in breast cancer cells in ONCOGENE
  • 2012-11-22. Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer in BRITISH JOURNAL OF CANCER
  • 2009-03-30. TrkA overexpression enhances growth and metastasis of breast cancer cells in ONCOGENE
  • 1995-02. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas in JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • 1997-01. Expression of TrkA, TrkB and TrkC in human neuroblastomas in JOURNAL OF NEURO-ONCOLOGY
  • 2004-01. Altered Expression and Activation of the Nerve Growth Factor Receptors TrkA and p75 Provide the First Evidence of Tumor Progression to Effusion in Breast Carcinoma in BREAST CANCER RESEARCH AND TREATMENT
  • 2010-08-07. K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells in INVESTIGATIONAL NEW DRUGS
  • 2011-10-14. More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2009-06-06. High-Throughput Screening of the Cyclic AMP-Dependent Protein Kinase (PKA) Using the Caliper Microfluidic Platform in HIGH THROUGHPUT SCREENING
  • 2011-02-22. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-05-24. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2006-03-29. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2004. TRK Oncogenes in Papillary Thyroid Carcinoma in MOLECULAR BASIS OF THYROID CANCER
  • 2013-10-27. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer in NATURE MEDICINE
  • Journal

    TITLE

    Cancer Chemotherapy and Pharmacology

    ISSUE

    1

    VOLUME

    75

    Related Patents

  • Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Molecules For Administration To Ros1 Mutant Cancer Cells
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Combinations For The Treatment Of Neuroblastoma
  • Methods For Treating Neuroblastoma
  • Method Of Treatment Using Substituted Pyrazolo[1,5-A] Pyrimidine Compounds
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Method Of Treatment Using Substituted Pyrazolo[1,5-A] Pyrimidine Compounds
  • Combinations For The Treatment Of Neuroblastoma
  • Macrocyclic Compounds As Trk Kinase Inhibitors
  • Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide
  • Method Of Treatment Using Substituted Pyrazolo[1,5-A] Pyrimidine Compounds
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Combinations For The Treatment Of Neuroblastoma
  • Combinations For The Treatment Of Cancer
  • Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Substituted Pyrazolo[L,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Macrocylic Compounds As Ros1 Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Method Of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  • Methods Of Treating Pediatric Cancers
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Point Mutations In Trk Inhibitor-Resistant Cancer And Methods Relating To The Same
  • Pharmaceutical Compositions And Dosage Forms
  • Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
  • Molecules For Administration To Ros1 Mutant Cancer Cells
  • Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1

    DOI

    http://dx.doi.org/10.1007/s00280-014-2627-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1003712700

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/25394774


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Camptothecin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dacarbazine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drugs, Investigational", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Half-Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Irinotecan", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Membrane Glycoproteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, Nude", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neuroblastoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphorylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Processing, Post-Translational", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, trkB", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Temozolomide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Burden", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Xenograft Model Antitumor Assays", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239552.a", 
              "name": [
                "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Croucher", 
            "givenName": "Jamie L.", 
            "id": "sg:person.01075773502.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075773502.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239552.a", 
              "name": [
                "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iyer", 
            "givenName": "Radhika", 
            "id": "sg:person.01320675661.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675661.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Li", 
            "givenName": "Nanxin", 
            "id": "sg:person.01206211573.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206211573.40"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Molteni", 
            "givenName": "Valentina", 
            "id": "sg:person.01135030213.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135030213.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Loren", 
            "givenName": "Jon", 
            "id": "sg:person.01364310610.59", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364310610.59"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gordon", 
            "givenName": "W. Perry", 
            "id": "sg:person.01164003500.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164003500.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tuntland", 
            "givenName": "Tove", 
            "id": "sg:person.01216641255.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216641255.69"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.418185.1", 
              "name": [
                "The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Liu", 
            "givenName": "Bo", 
            "id": "sg:person.0767173005.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767173005.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.239552.a", 
              "name": [
                "Oncology Research, The Children\u2019s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Brodeur", 
            "givenName": "Garrett M.", 
            "id": "sg:person.015450030517.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015450030517.11"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/1-4020-8107-3_12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052428201", 
              "https://doi.org/10.1007/1-4020-8107-3_12"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-005-5490-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008991250", 
              "https://doi.org/10.1007/s00018-005-5490-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206805", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029788448", 
              "https://doi.org/10.1038/sj.onc.1206805"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-010-9513-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038591843", 
              "https://doi.org/10.1007/s10637-010-9513-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0298-184", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047807659", 
              "https://doi.org/10.1038/ng0298-184"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-60327-258-2_11", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032321217", 
              "https://doi.org/10.1007/978-1-60327-258-2_11"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1756-9966-30-97", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037031427", 
              "https://doi.org/10.1186/1756-9966-30-97"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/374450a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050386837", 
              "https://doi.org/10.1038/374450a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-012-1879-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043514230", 
              "https://doi.org/10.1007/s00280-012-1879-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03349721", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025319217", 
              "https://doi.org/10.1007/bf03349721"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800050656", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006526423", 
              "https://doi.org/10.1007/s002800050656"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006652605568", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048857885", 
              "https://doi.org/10.1023/a:1006652605568"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008818340", 
              "https://doi.org/10.1038/nrc1014"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-011-1581-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046099568", 
              "https://doi.org/10.1007/s00280-011-1581-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1005729329526", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044022705", 
              "https://doi.org/10.1023/a:1005729329526"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2012.499", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023531873", 
              "https://doi.org/10.1038/bjc.2012.499"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/b:brea.0000010704.17479.8a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040004777", 
              "https://doi.org/10.1023/b:brea.0000010704.17479.8a"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.3352", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040347765", 
              "https://doi.org/10.1038/nm.3352"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2009.61", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012479383", 
              "https://doi.org/10.1038/onc.2009.61"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-11-14", 
        "datePublishedReg": "2014-11-14", 
        "description": "Purpose\nNeuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50\u201360\u00a0% of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.Methods\nWe tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino\u2013TMZ).ResultsGNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50\u00a0nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p\u00a0<\u00a00.0001 for mice treated at 40 or 100\u00a0mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino\u2013TMZ, p\u00a0<\u00a00.0071 compared to Irino\u2013TMZ alone).ConclusionsOur data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino\u2013TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00280-014-2627-1", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2475910", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1088364", 
            "issn": [
              "0344-5704", 
              "1432-0843"
            ], 
            "name": "Cancer Chemotherapy and Pharmacology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "75"
          }
        ], 
        "keywords": [
          "brain-derived neurotrophic factor", 
          "high-risk neuroblastoma", 
          "additional toxicity", 
          "event-free survival", 
          "refractory high-risk neuroblastoma", 
          "antitumor efficacy", 
          "tropomyosin receptor kinase family", 
          "pan-Trk inhibitors", 
          "intensive multimodality therapy", 
          "disparate clinical behaviors", 
          "inhibition of TrkB", 
          "pediatric solid tumors", 
          "dose-dependent manner", 
          "vivo growth inhibition", 
          "conventional chemotherapeutic agents", 
          "xenograft mouse model", 
          "mouse xenograft model", 
          "human NB cells", 
          "current chemotherapeutic treatment", 
          "growth inhibition", 
          "TrkB phosphorylation", 
          "TrkB inhibition", 
          "multimodality therapy", 
          "NB xenografts", 
          "cell growth inhibition", 
          "neuroblastoma xenografts", 
          "ConclusionsOur data", 
          "relentless progression", 
          "spontaneous regression", 
          "neurotrophic factor", 
          "clinical behavior", 
          "nu/", 
          "autocrine pathway", 
          "clinical heterogeneity", 
          "mouse model", 
          "single agent", 
          "xenograft model", 
          "chemotherapeutic treatment", 
          "TrkB", 
          "NB cells", 
          "Trk inhibitors", 
          "solid tumors", 
          "neuroblastoma", 
          "chemotherapeutic agents", 
          "drug resistance", 
          "chemotherapeutic efficacy", 
          "efficacy", 
          "xenografts", 
          "inhibition", 
          "vivo", 
          "survival", 
          "receptor kinase family", 
          "vitro", 
          "compelling evidence", 
          "inhibitors", 
          "toxicity", 
          "temozolomide", 
          "metastasis", 
          "therapy", 
          "agents", 
          "tumors", 
          "important role", 
          "progression", 
          "angiogenesis", 
          "treatment", 
          "invasion", 
          "IC50", 
          "kinase family", 
          "regression", 
          "cells", 
          "nM", 
          "pathway", 
          "phosphorylation", 
          "evidence", 
          "factors", 
          "data", 
          "growth", 
          "role", 
          "resistance", 
          "heterogeneity", 
          "manner", 
          "purpose", 
          "family", 
          "ability", 
          "addition", 
          "members", 
          "ligands", 
          "model", 
          "method", 
          "behavior", 
          "deadly pediatric solid tumors", 
          "BDNF/TrkB autocrine pathway", 
          "TrkB autocrine pathway", 
          "novel pan-Trk inhibitor", 
          "GNF-4256", 
          "athymic xenograft mouse model", 
          "growth of TrkB", 
          "ability of GNF-4256", 
          "NB cell growth inhibition", 
          "ResultsGNF-4256 inhibits TrkB phosphorylation", 
          "inhibits TrkB phosphorylation", 
          "specific Trk inhibitor", 
          "SY5Y-TrkB growth", 
          "addition of GNF-4256", 
          "Irino\u2013TMZ", 
          "recurrent/refractory high-risk NBs"
        ], 
        "name": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts", 
        "pagination": "131-141", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1003712700"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00280-014-2627-1"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "25394774"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00280-014-2627-1", 
          "https://app.dimensions.ai/details/publication/pub.1003712700"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_619.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00280-014-2627-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2627-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    405 TRIPLES      22 PREDICATES      176 URIs      149 LITERALS      32 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00280-014-2627-1 schema:about N02af59e0e27c40ea8d675bcacffb45e3
    2 N0500040228bd433f8270b1c50c1e04ec
    3 N0b2afecf1e264ab8b3d9c1e990c465ba
    4 N107a68c9f0aa446f995aebe2136c7f06
    5 N1524401ffd0e451192c11b7fc593d382
    6 N2c45bf9720d04e999ddb1e10cea9f4bd
    7 N358d3e9c930c46f880b50c9b29435d7a
    8 N39351df15d244355b706ba09f8ee7a16
    9 N3a3c97c9ac1347f3b83ef02048ddf3ed
    10 N49aff80d15a3470995102ed28ba7cc48
    11 N4d2000cfbf494826a74204996b0fd470
    12 N4d5d8ca696d8491093c2f6e5d3b7c64d
    13 N52ddaa7d6e95403bb1a83634501a17d2
    14 N564dbf126800468d9e53a2c66e62319a
    15 N5860722822aa4a66bfd46ce61456e51c
    16 N5b58a9c7a3ab471589c8184fe2cdae98
    17 N62918f3d1f7b475ea04fbe1b8fc1a86c
    18 N794995f2f6704298b0e5a37f7e1f1895
    19 Na3e7bb92849f4ee09ce85caba7caa446
    20 Nbd0001b5c3a245fd80b0fbf16ed0f811
    21 Ncad58d1f2a6c4e37bf6360de55da38e2
    22 Ncfe8155581d047f9b1dcc094016a3ccc
    23 Ne01b7b49cc1e4ecf95b76b71f322d216
    24 Ne5439c5fa0404695806d9fc8e604dd3f
    25 Nf9d89b90814949248c68664418099d85
    26 anzsrc-for:11
    27 anzsrc-for:1115
    28 schema:author Nfadf7d3797234202bd15b114530aab10
    29 schema:citation sg:pub.10.1007/1-4020-8107-3_12
    30 sg:pub.10.1007/978-1-60327-258-2_11
    31 sg:pub.10.1007/bf03349721
    32 sg:pub.10.1007/s00018-005-5490-8
    33 sg:pub.10.1007/s00280-011-1581-4
    34 sg:pub.10.1007/s00280-012-1879-x
    35 sg:pub.10.1007/s002800050656
    36 sg:pub.10.1007/s10637-010-9513-4
    37 sg:pub.10.1023/a:1005729329526
    38 sg:pub.10.1023/a:1006652605568
    39 sg:pub.10.1023/b:brea.0000010704.17479.8a
    40 sg:pub.10.1038/374450a0
    41 sg:pub.10.1038/bjc.2012.499
    42 sg:pub.10.1038/ng0298-184
    43 sg:pub.10.1038/nm.3352
    44 sg:pub.10.1038/nrc1014
    45 sg:pub.10.1038/onc.2009.61
    46 sg:pub.10.1038/sj.onc.1206805
    47 sg:pub.10.1186/1756-9966-30-97
    48 schema:datePublished 2014-11-14
    49 schema:datePublishedReg 2014-11-14
    50 schema:description Purpose Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to relentless progression despite intensive multimodality therapy. There is compelling evidence that members of the tropomyosin receptor kinase (Trk) family play important roles in these disparate clinical behaviors. Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50–60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance.Methods We tested a novel pan-Trk inhibitor, GNF-4256 (Genomics Institute of the Novartis Research Foundation), in vitro and in vivo in a nu/nu athymic xenograft mouse model to determine its efficacy in inhibiting the growth of TrkB-expressing human NB cells (SY5Y-TrkB). Additionally, we assessed the ability of GNF-4256 to enhance NB cell growth inhibition in vitro and in vivo, when combined with conventional chemotherapeutic agents, irinotecan and temozolomide (Irino–TMZ).ResultsGNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner, with an IC50 around 7 and 50 nM, respectively. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent (p < 0.0001 for mice treated at 40 or 100 mg/kg BID, compared to controls), and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino–TMZ, p < 0.0071 compared to Irino–TMZ alone).ConclusionsOur data suggest that GNF-4256 is a potent and specific Trk inhibitor capable of significantly slowing SY5Y-TrkB growth, both in vitro and in vivo. More importantly, the addition of GNF-4256 significantly enhanced the antitumor efficacy of Irino–TMZ, as measured by in vitro and in vivo growth inhibition and increased event-free survival in a mouse xenograft model, without additional toxicity. These data strongly suggest that inhibition of TrkB with GNF-4256 can enhance the efficacy of current chemotherapeutic treatment for recurrent/refractory high-risk NBs with minimal or no additional toxicity.
    51 schema:genre article
    52 schema:inLanguage en
    53 schema:isAccessibleForFree true
    54 schema:isPartOf N33d65e6e53c7472b953edeeb0641dcd5
    55 Nd83bee8a69dd41ceb01a2cab0eb84350
    56 sg:journal.1088364
    57 schema:keywords BDNF/TrkB autocrine pathway
    58 ConclusionsOur data
    59 GNF-4256
    60 IC50
    61 Irino–TMZ
    62 NB cell growth inhibition
    63 NB cells
    64 NB xenografts
    65 ResultsGNF-4256 inhibits TrkB phosphorylation
    66 SY5Y-TrkB growth
    67 Trk inhibitors
    68 TrkB
    69 TrkB autocrine pathway
    70 TrkB inhibition
    71 TrkB phosphorylation
    72 ability
    73 ability of GNF-4256
    74 addition
    75 addition of GNF-4256
    76 additional toxicity
    77 agents
    78 angiogenesis
    79 antitumor efficacy
    80 athymic xenograft mouse model
    81 autocrine pathway
    82 behavior
    83 brain-derived neurotrophic factor
    84 cell growth inhibition
    85 cells
    86 chemotherapeutic agents
    87 chemotherapeutic efficacy
    88 chemotherapeutic treatment
    89 clinical behavior
    90 clinical heterogeneity
    91 compelling evidence
    92 conventional chemotherapeutic agents
    93 current chemotherapeutic treatment
    94 data
    95 deadly pediatric solid tumors
    96 disparate clinical behaviors
    97 dose-dependent manner
    98 drug resistance
    99 efficacy
    100 event-free survival
    101 evidence
    102 factors
    103 family
    104 growth
    105 growth inhibition
    106 growth of TrkB
    107 heterogeneity
    108 high-risk neuroblastoma
    109 human NB cells
    110 important role
    111 inhibition
    112 inhibition of TrkB
    113 inhibitors
    114 inhibits TrkB phosphorylation
    115 intensive multimodality therapy
    116 invasion
    117 kinase family
    118 ligands
    119 manner
    120 members
    121 metastasis
    122 method
    123 model
    124 mouse model
    125 mouse xenograft model
    126 multimodality therapy
    127 nM
    128 neuroblastoma
    129 neuroblastoma xenografts
    130 neurotrophic factor
    131 novel pan-Trk inhibitor
    132 nu/
    133 pan-Trk inhibitors
    134 pathway
    135 pediatric solid tumors
    136 phosphorylation
    137 progression
    138 purpose
    139 receptor kinase family
    140 recurrent/refractory high-risk NBs
    141 refractory high-risk neuroblastoma
    142 regression
    143 relentless progression
    144 resistance
    145 role
    146 single agent
    147 solid tumors
    148 specific Trk inhibitor
    149 spontaneous regression
    150 survival
    151 temozolomide
    152 therapy
    153 toxicity
    154 treatment
    155 tropomyosin receptor kinase family
    156 tumors
    157 vitro
    158 vivo
    159 vivo growth inhibition
    160 xenograft model
    161 xenograft mouse model
    162 xenografts
    163 schema:name TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
    164 schema:pagination 131-141
    165 schema:productId N51bd6af7ada847f78ea081cf078f9de5
    166 N88b4278caafb430ea1e342b147c761e0
    167 Nf51a9a01406f47e7ba06257ff5635777
    168 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003712700
    169 https://doi.org/10.1007/s00280-014-2627-1
    170 schema:sdDatePublished 2021-11-01T18:21
    171 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    172 schema:sdPublisher Nad9c9c4a9995470dadf89490c3009978
    173 schema:url https://doi.org/10.1007/s00280-014-2627-1
    174 sgo:license sg:explorer/license/
    175 sgo:sdDataset articles
    176 rdf:type schema:ScholarlyArticle
    177 N02af59e0e27c40ea8d675bcacffb45e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Temozolomide
    179 rdf:type schema:DefinedTerm
    180 N0500040228bd433f8270b1c50c1e04ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Cell Survival
    182 rdf:type schema:DefinedTerm
    183 N0b2afecf1e264ab8b3d9c1e990c465ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Phosphorylation
    185 rdf:type schema:DefinedTerm
    186 N107a68c9f0aa446f995aebe2136c7f06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Membrane Glycoproteins
    188 rdf:type schema:DefinedTerm
    189 N1524401ffd0e451192c11b7fc593d382 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Camptothecin
    191 rdf:type schema:DefinedTerm
    192 N19150daaa438483a86b110aa9a94f32d rdf:first sg:person.015450030517.11
    193 rdf:rest rdf:nil
    194 N2c45bf9720d04e999ddb1e10cea9f4bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Survival Analysis
    196 rdf:type schema:DefinedTerm
    197 N33d65e6e53c7472b953edeeb0641dcd5 schema:issueNumber 1
    198 rdf:type schema:PublicationIssue
    199 N358d3e9c930c46f880b50c9b29435d7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Neoplasm Proteins
    201 rdf:type schema:DefinedTerm
    202 N39351df15d244355b706ba09f8ee7a16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Protein Processing, Post-Translational
    204 rdf:type schema:DefinedTerm
    205 N3a3c97c9ac1347f3b83ef02048ddf3ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Humans
    207 rdf:type schema:DefinedTerm
    208 N49aff80d15a3470995102ed28ba7cc48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Mice, Nude
    210 rdf:type schema:DefinedTerm
    211 N4d2000cfbf494826a74204996b0fd470 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    212 schema:name Antineoplastic Agents
    213 rdf:type schema:DefinedTerm
    214 N4d5d8ca696d8491093c2f6e5d3b7c64d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    215 schema:name Half-Life
    216 rdf:type schema:DefinedTerm
    217 N51bd6af7ada847f78ea081cf078f9de5 schema:name pubmed_id
    218 schema:value 25394774
    219 rdf:type schema:PropertyValue
    220 N52ddaa7d6e95403bb1a83634501a17d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    221 schema:name Drugs, Investigational
    222 rdf:type schema:DefinedTerm
    223 N564dbf126800468d9e53a2c66e62319a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    224 schema:name Animals
    225 rdf:type schema:DefinedTerm
    226 N5860722822aa4a66bfd46ce61456e51c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    227 schema:name Protein Kinase Inhibitors
    228 rdf:type schema:DefinedTerm
    229 N590e4eecc8514ff9831f559304c30cbf rdf:first sg:person.0767173005.51
    230 rdf:rest N19150daaa438483a86b110aa9a94f32d
    231 N5b58a9c7a3ab471589c8184fe2cdae98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    232 schema:name Irinotecan
    233 rdf:type schema:DefinedTerm
    234 N62918f3d1f7b475ea04fbe1b8fc1a86c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    235 schema:name Dacarbazine
    236 rdf:type schema:DefinedTerm
    237 N75d2c581a9f4456a82abd0f667e44961 rdf:first sg:person.01216641255.69
    238 rdf:rest N590e4eecc8514ff9831f559304c30cbf
    239 N794995f2f6704298b0e5a37f7e1f1895 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    240 schema:name Tumor Burden
    241 rdf:type schema:DefinedTerm
    242 N8112231e5fd04d5ab7a9215823f1ca7b rdf:first sg:person.01164003500.96
    243 rdf:rest N75d2c581a9f4456a82abd0f667e44961
    244 N88b4278caafb430ea1e342b147c761e0 schema:name doi
    245 schema:value 10.1007/s00280-014-2627-1
    246 rdf:type schema:PropertyValue
    247 Na3e7bb92849f4ee09ce85caba7caa446 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    248 schema:name Receptor, trkB
    249 rdf:type schema:DefinedTerm
    250 Nad9c9c4a9995470dadf89490c3009978 schema:name Springer Nature - SN SciGraph project
    251 rdf:type schema:Organization
    252 Nba1b4edf128f4c6a82101f6f1f4ac967 rdf:first sg:person.01206211573.40
    253 rdf:rest Nd056b781d2634d35a8ebcdd67fb58d9d
    254 Nbd0001b5c3a245fd80b0fbf16ed0f811 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    255 schema:name Antineoplastic Combined Chemotherapy Protocols
    256 rdf:type schema:DefinedTerm
    257 Ncad58d1f2a6c4e37bf6360de55da38e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    258 schema:name Cell Line, Tumor
    259 rdf:type schema:DefinedTerm
    260 Ncfe8155581d047f9b1dcc094016a3ccc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    261 schema:name Protein-Tyrosine Kinases
    262 rdf:type schema:DefinedTerm
    263 Nd056b781d2634d35a8ebcdd67fb58d9d rdf:first sg:person.01135030213.08
    264 rdf:rest Ne61fcdc2091c4cacab21e554d0d32a2e
    265 Nd83bee8a69dd41ceb01a2cab0eb84350 schema:volumeNumber 75
    266 rdf:type schema:PublicationVolume
    267 Ne01b7b49cc1e4ecf95b76b71f322d216 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    268 schema:name Xenograft Model Antitumor Assays
    269 rdf:type schema:DefinedTerm
    270 Ne5439c5fa0404695806d9fc8e604dd3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    271 schema:name Dose-Response Relationship, Drug
    272 rdf:type schema:DefinedTerm
    273 Ne61fcdc2091c4cacab21e554d0d32a2e rdf:first sg:person.01364310610.59
    274 rdf:rest N8112231e5fd04d5ab7a9215823f1ca7b
    275 Ne6e485357ffd4b2bb955c520318505db rdf:first sg:person.01320675661.33
    276 rdf:rest Nba1b4edf128f4c6a82101f6f1f4ac967
    277 Nf51a9a01406f47e7ba06257ff5635777 schema:name dimensions_id
    278 schema:value pub.1003712700
    279 rdf:type schema:PropertyValue
    280 Nf9d89b90814949248c68664418099d85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    281 schema:name Neuroblastoma
    282 rdf:type schema:DefinedTerm
    283 Nfadf7d3797234202bd15b114530aab10 rdf:first sg:person.01075773502.36
    284 rdf:rest Ne6e485357ffd4b2bb955c520318505db
    285 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    286 schema:name Medical and Health Sciences
    287 rdf:type schema:DefinedTerm
    288 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    289 schema:name Pharmacology and Pharmaceutical Sciences
    290 rdf:type schema:DefinedTerm
    291 sg:grant.2475910 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-014-2627-1
    292 rdf:type schema:MonetaryGrant
    293 sg:journal.1088364 schema:issn 0344-5704
    294 1432-0843
    295 schema:name Cancer Chemotherapy and Pharmacology
    296 schema:publisher Springer Nature
    297 rdf:type schema:Periodical
    298 sg:person.01075773502.36 schema:affiliation grid-institutes:grid.239552.a
    299 schema:familyName Croucher
    300 schema:givenName Jamie L.
    301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075773502.36
    302 rdf:type schema:Person
    303 sg:person.01135030213.08 schema:affiliation grid-institutes:grid.418185.1
    304 schema:familyName Molteni
    305 schema:givenName Valentina
    306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135030213.08
    307 rdf:type schema:Person
    308 sg:person.01164003500.96 schema:affiliation grid-institutes:grid.418185.1
    309 schema:familyName Gordon
    310 schema:givenName W. Perry
    311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164003500.96
    312 rdf:type schema:Person
    313 sg:person.01206211573.40 schema:affiliation grid-institutes:grid.418185.1
    314 schema:familyName Li
    315 schema:givenName Nanxin
    316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206211573.40
    317 rdf:type schema:Person
    318 sg:person.01216641255.69 schema:affiliation grid-institutes:grid.418185.1
    319 schema:familyName Tuntland
    320 schema:givenName Tove
    321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216641255.69
    322 rdf:type schema:Person
    323 sg:person.01320675661.33 schema:affiliation grid-institutes:grid.239552.a
    324 schema:familyName Iyer
    325 schema:givenName Radhika
    326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675661.33
    327 rdf:type schema:Person
    328 sg:person.01364310610.59 schema:affiliation grid-institutes:grid.418185.1
    329 schema:familyName Loren
    330 schema:givenName Jon
    331 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364310610.59
    332 rdf:type schema:Person
    333 sg:person.015450030517.11 schema:affiliation grid-institutes:grid.239552.a
    334 schema:familyName Brodeur
    335 schema:givenName Garrett M.
    336 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015450030517.11
    337 rdf:type schema:Person
    338 sg:person.0767173005.51 schema:affiliation grid-institutes:grid.418185.1
    339 schema:familyName Liu
    340 schema:givenName Bo
    341 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767173005.51
    342 rdf:type schema:Person
    343 sg:pub.10.1007/1-4020-8107-3_12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052428201
    344 https://doi.org/10.1007/1-4020-8107-3_12
    345 rdf:type schema:CreativeWork
    346 sg:pub.10.1007/978-1-60327-258-2_11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032321217
    347 https://doi.org/10.1007/978-1-60327-258-2_11
    348 rdf:type schema:CreativeWork
    349 sg:pub.10.1007/bf03349721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025319217
    350 https://doi.org/10.1007/bf03349721
    351 rdf:type schema:CreativeWork
    352 sg:pub.10.1007/s00018-005-5490-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008991250
    353 https://doi.org/10.1007/s00018-005-5490-8
    354 rdf:type schema:CreativeWork
    355 sg:pub.10.1007/s00280-011-1581-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046099568
    356 https://doi.org/10.1007/s00280-011-1581-4
    357 rdf:type schema:CreativeWork
    358 sg:pub.10.1007/s00280-012-1879-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043514230
    359 https://doi.org/10.1007/s00280-012-1879-x
    360 rdf:type schema:CreativeWork
    361 sg:pub.10.1007/s002800050656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006526423
    362 https://doi.org/10.1007/s002800050656
    363 rdf:type schema:CreativeWork
    364 sg:pub.10.1007/s10637-010-9513-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038591843
    365 https://doi.org/10.1007/s10637-010-9513-4
    366 rdf:type schema:CreativeWork
    367 sg:pub.10.1023/a:1005729329526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044022705
    368 https://doi.org/10.1023/a:1005729329526
    369 rdf:type schema:CreativeWork
    370 sg:pub.10.1023/a:1006652605568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048857885
    371 https://doi.org/10.1023/a:1006652605568
    372 rdf:type schema:CreativeWork
    373 sg:pub.10.1023/b:brea.0000010704.17479.8a schema:sameAs https://app.dimensions.ai/details/publication/pub.1040004777
    374 https://doi.org/10.1023/b:brea.0000010704.17479.8a
    375 rdf:type schema:CreativeWork
    376 sg:pub.10.1038/374450a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050386837
    377 https://doi.org/10.1038/374450a0
    378 rdf:type schema:CreativeWork
    379 sg:pub.10.1038/bjc.2012.499 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023531873
    380 https://doi.org/10.1038/bjc.2012.499
    381 rdf:type schema:CreativeWork
    382 sg:pub.10.1038/ng0298-184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047807659
    383 https://doi.org/10.1038/ng0298-184
    384 rdf:type schema:CreativeWork
    385 sg:pub.10.1038/nm.3352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040347765
    386 https://doi.org/10.1038/nm.3352
    387 rdf:type schema:CreativeWork
    388 sg:pub.10.1038/nrc1014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008818340
    389 https://doi.org/10.1038/nrc1014
    390 rdf:type schema:CreativeWork
    391 sg:pub.10.1038/onc.2009.61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012479383
    392 https://doi.org/10.1038/onc.2009.61
    393 rdf:type schema:CreativeWork
    394 sg:pub.10.1038/sj.onc.1206805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029788448
    395 https://doi.org/10.1038/sj.onc.1206805
    396 rdf:type schema:CreativeWork
    397 sg:pub.10.1186/1756-9966-30-97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037031427
    398 https://doi.org/10.1186/1756-9966-30-97
    399 rdf:type schema:CreativeWork
    400 grid-institutes:grid.239552.a schema:alternateName Oncology Research, The Children’s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA
    401 schema:name Oncology Research, The Children’s Hospital of Philadelphia, CTRB Rm. 3018, 3501 Civic Center Blvd., 19104-4302, Philadelphia, PA, USA
    402 rdf:type schema:Organization
    403 grid-institutes:grid.418185.1 schema:alternateName The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA
    404 schema:name The Genomics Institute of the Novartis Research Foundation, 92121, San Diego, CA, USA
    405 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...